Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): Keynote-087 Meeting Abstract
| Authors: | Chen, R.; Armand, P.; Fanale, M. A.; Ribrag, V.; Zinzani, P. L.; Ricart, A. D.; Thompson, S.; Balakumaran, A.; Molin, D.; Shipp, M. A.; Moskowitz, C. H. |
| Abstract Title: | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): Keynote-087 |
| Meeting Title: | 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC 2015) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 3 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2015 Nov 4-8 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2015-11-04 |
| Language: | English |
| DOI: | 10.1186/2051-1426-3-S2-P146 |
| PROVIDER: | manual |
| PMCID: | PMC4645991 |
| Notes: | Meeting Abstract: P146 |
